At the NICAR 2026 conference, dozens of leading data journalists shared some of their favorite digital tools and databases for investigating numerous topics.

Psychedelic drug developer Compass Pathways is preparing to talk to the FDA about filing its psilocybin therapy COMP360 for approval in treatment-resistant depression (TRD), after reporting positive ...

This indepth Claude tutorial explains Projects, Skills, and Connectors as well as connecting Gmail, Slack, and Drive links, plus a workflow setup checklist ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced that tomorrow it will report new clinical data from two ...

Compass Therapeutics, Inc. is set to report fourth-quarter and full-year 2025 results on Friday, with investors focused less on the biotech’s expected loss and more on progress toward a potential ...

LONDON & NEW YORK, February 16, 2026--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced ...

The Brookfield-owned hyperscale developer is planning to issue asset-backed securities backed by six new, fully leased data centers in Phoenix and Toronto, according to a presale report from Moody’s ...

Compass Group PLC CPG shares slid 2.07% to £20.81 Monday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.16% to 10,386.23.

The crypto market may be closing in on the bottom of its current downturn, but analysts at Compass Point say it will take a broader risk-off event to push bitcoin BTC $73,685.87 significantly lower.